Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial.
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the competitive field.
Novo Nordisk Obesity Drug Achieves Up to 22% Weight Loss in Clinical Trial
Novo Nordisk's (NVO) said Friday that its investigative weight loss drug, amycretin, led to a body weight reduction of up to 22% in an early-stage trial. The maker of obesity drug Wegovy and diabetes treatment Ozempic said its phase 1b/2a trial covered 125 overweight people.
Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms
Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.
Explainer: What Wegovy's inclusion in Medicare price negotiation means for patients, company
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...
How Trump’s Greenland demands could impact Ozempic costs
Trump added Denmark to his growing list of tariff targets — including Canada, Mexico and China — as he has increasingly ...
devdiscourse3d
European Shares Steady Amid Trade Tensions and Financial Gains
European shares held steady with slight gains in financials and healthcare despite global uncertainties over U.S. President Donald Trump's proposed tariffs. The market's cautious optimism was ...
There is a 'valley of death' in European research and innovation, says CEO of Novo Nordisk Foundation
Mads Krogsgaard Thomsen, CEO of Novo Nordisk Foundation, discusses European competitiveness.
Business Recorder2d
Healthcare, luxury stocks boost STOXX 600 to 3-month high
FRANKFURT: European shares rose on Tuesday, buoyed by gains in the healthcare and luxury sectors, but the uptick ...
European share markets steady as healthcare, financial stocks offset Trump’s tariff fears
European markets were subdued on Tuesday, with the STOXX 600 up 0.1 percent as healthcare and financials gains offset losses ...
S&P 500 ekes new record in muted open. As tariff worries ease, eyes turn to company news
US stocks subdued at open, but S&P 500 inches up to a record high for third straight day. As tariff worries ease for now, ...
TSX Flat at Open
Canada's main stock index opened slightly higher on Friday as mining stocks added support, but losses in industrials shares limited gains. The TSX index dipped 0.04 points to start Friday at 25,434.04 ...